Group 1 - The Hong Kong stock market showed strong performance on June 5, with the Hang Seng Index rising by 0.93% and the Hang Seng Tech Index increasing by 1.5% [1] - The Hang Seng Medical Index ETF (159557) rose by 0.81% with a turnover rate of 7.52%, indicating active trading [1] - Notable performers among the constituent stocks included Four Seasons Medicine and Hutchison China MediTech, both rising over 7%, while Zai Lab increased by over 6% and CanSino Biologics rose by over 5% [1] Group 2 - According to industrial analysts, demand in the domestic market is expected to recover by 2025, with a positive outlook for the consumption medical sector, including medical services, OTC traditional Chinese medicine, and chain pharmacies [2] - The medical device sector is also anticipated to improve by 2025, with AI in healthcare expected to bring significant changes to the pharmaceutical industry [2] - China's innovative drugs have gained recognition from large overseas pharmaceutical companies, indicating that the country's R&D capabilities are now internationally competitive, which is expected to drive performance growth [2]
恒生医疗指数ETF(159557)走高,康方生物涨超5%,机构:创新药板块景气度可持续